Hormone Replacement Therapy

Article Author:
Gina Harper-Harrison
Article Editor:
Meaghan Shanahan
10/27/2018 12:31:37 PM
PubMed Link:
Hormone Replacement Therapy


Hormone replacement therapy (HRT) is supplementing women with hormones that are lost during the menopausal transition. To relieve the symptoms associated with menopause, conventional HRT includes an estrogen and progesterone component to mimic hormones created by the human ovary.

Estrogen therapies are numerous, and include those indigenous to the human ovary, for example, estradiol and estriol. Other estrogenic compounds include conjugated equine estrogen (CEE), the most commonly prescribed estrogen in the United States. They are not identical in their effect on the human body but share the same FDA indications according to the Physicians Desk Reference. The indications for menopausal issues include:

  • Treatment of vasomotor symptoms of menopause
  • Treatment of genitourinary syndrome of menopause ( previously known as vaginal and vulvar atrophy)
  • Prevention of osteoporosis

Progestogen is a term used to include not only progesterone made by the human ovary but also progesterone-like substances, also known as progestins. A woman who desires HRT and has an intact uterus must have a progestogen with estrogen to protect her uterus from endometrial hyperplasia or malignancy. Estrogen alone will cause the endometrial lining to grow. Progestogens stabilize the lining from proliferating abnormally. It is assumed that if a woman has had a hysterectomy that she no longer needs a progestin. Progesterone, however, is different as it can provide symptom relief from sleep disturbance and mood instability and increasing evidence support that it offers tissue protection to the breast.

FDA-approved indications for progestogens include:

  •  Amenorrhea, either primary or secondary
  •  Assisted reproductive technology treatment
  •  Endometrial hyperplasia
  •  Dysfunctional uterine bleeding


There are numerous estrogen and progestogen choices, and they may be administrated orally or transdermally either through cream, patch, vaginal inserts, or subdermal pellets. Each route of administration has unique benefits and risks.

Oral Estrogen: Any estrogen administered orally results in increased activated protein-C resistance, increasing the risk of a blood clot. Oral estradiol also induces the hepatic formation of matrix metalloprotease 9, which decreases the formation and rupture of atherosclerotic plaque.

Transdermal Estrogen: Bypasses the hepatic metabolism that produces activated protein-C resistance, and the risk for blood clotting is negated.

Progestins are usually administered orally, although a few are available in combination with estrogen in patch forms. Progesterone is available in an oral form that can also be used vaginally for non-FDA-approved uses.

Specialized pharmacies make compounded estrogen and progesterone creams, sublingual troches, and vaginal inserts, but these are not FDA approved and are not be included in this article.

Adverse Effects

When studying the potential adverse effects of HRT, the most referenced information in the United States comes from the Women's Health Initiative (WHI).

WHI Trial

This was a multifaceted trial, including 2 double-blind, placebo-controlled, randomized trials of postmenopausal hormone therapy.

The first arm included CEE at 0.625 mg per day with medroxyprogesterone acetate (MPA) 2.5 mg per day. The second arm was comprised of patients who had prior hysterectomies and treated with CEE 0.625 mg only.

HRT and the Breast

The CEE/MPA arm was discontinued earlier than expected due to an increased incidence of invasive breast cancer of 24% (HR=1.24). The CEE only arm was not discontinued early, completed in 2004, and extended follow up of patients has continued for 11.8 years. CEE use for 5 to 9 years is associated with a statistically significant reduction in breast cancer by 23% (HR=0.77). Those in the CEE arm also had decreased mortality from breast cancer by 63% compared to those not on CEE, and 38% fewer died from all other causes after breast cancer was diagnosed.

When examining evidence from European studies which usually use estradiol derivatives rather than CEE, and non-MPA progesterone or progestins, the conclusions are vastly different and unequal. Transdermal estradiol alone increased the risk of breast cancer by 10%, but with progesterone decreased the risk of breast cancer by 10%.

HRT and the Heart

In the WHI CEE/MPA arm, the overall incidence of coronary heart disease (CHD) increased by 24% over 5 years of use, with the most substantial elevation in risk within the first year, with an increase of 81% (HR=1.81). This evidence needs to be interpreted with caution due to the following:

  • The average age of the patient treated in this study was 62 years. In women who were started on therapy within 10 years of menopause, the risk of CAD was reduced by 11% (HR=0.89), but this was not found to be statistically significant.
  • In those women who continued CEE/MPA for over 6 years, the risk of CAD was lowered by 30% (HR=0.70).

These risks do not apply to estradiol and progesterone based treatments. Basic science studies show several mechanisms through which estradiol (not CEE) is cardioprotective. These include stabilization of atherosclerotic plaques, reduction of carotid intima-media thickness (CIMT), and decreasing coronary artery calcium (CAC) scores. Numerous subsequent studies both in Europe and the United States show that cardiovascular disease and death are prominently reduced when HRT is initiated within the first 4 years of the menopause transition. The "Timing Hypothesis" refers to the theory that when HRT is initiated closer to the time of the menopause transition, a cardiovascular benefit is seen compared with later initiation.

HRT and Risk of Stroke

Stroke incidence increased in both arms of the WHI trial by 31% in the CEE/MPA arm, and 39% in the CEE arm.

Studies using oral estradiol are conflicted, showing a similar stroke risk, but the incidence of fatal stroke is unchanged.

HRT and the Risk of Venous Thromboembolism (VTE)

VTE, comprised of deep venous thrombosis and pulmonary embolism, was increased by 2-fold (HR= 2.06) in the WHI CEE/MPA arm.

Transdermal estradiol does not confer the same thromboembolic risk, as is evidenced by numerous European studies. The ESTHER study from France showed an overall risk of 0.9 for a blood clot, which is a decreased risk. Subsequent studies looking at other transdermal estradiol doses and routes confirm these findings, with at least a null effect for blood-clotting risk.


Contraindications for oral or transdermal estrogen-based therapies include:

  • Known, suspected or history of breast cancer
  • Known or suspected history of other estrogen-based cancer, i.e., uterine cancer. Women who have had a hysterectomy and have no remaining evidence of disease are still candidates for HRT
  • Active deep venous thrombosis (DVT) or a history of DVT or pulmonary embolism (PE)
  • History of blood clotting disorder, the most common being Factor V Leiden mutation carriers
  • Active or history of arterial thrombotic diseases such as myocardial infarction or stroke
  • Chronic liver disease or dysfunction

These contraindications do not apply to transvaginal based estrogen therapies, as the serum concentration of estrogen from this route is extremely low. The North American Menopause Society (NAMS) has recommended that the black-box warning that applies to conventional HRT not be applied to transvaginal estrogen treatments.


Hormone levels of estradiol and progesterone are not traditionally done for monitoring purposes. Rather, the relief of menopausal symptoms and the absence of adverse effects signify an adequate medical response.

Adverse side effects may include:

  • Abnormal uterine bleeding
  • Fluid retention
  • Breast tenderness
  • Headaches
  • Mood changes

No scientific evidence links HRT with significant weight gain.

HRT including androgen therapies such as testosterone should be monitored with serum testing but is not considered conventional HRT.


Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial., Chlebowski RT,Hendrix SL,Langer RD,Stefanick ML,Gass M,Lane D,Rodabough RJ,Gilligan MA,Cyr MG,Thomson CA,Khandekar J,Petrovitch H,McTiernan A,, JAMA, 2003 Jun 25     [PubMed PMID: 12824205]
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial., Anderson GL,Chlebowski RT,Aragaki AK,Kuller LH,Manson JE,Gass M,Bluhm E,Connelly S,Hubbell FA,Lane D,Martin L,Ockene J,Rohan T,Schenken R,Wactawski-Wende J,, The Lancet. Oncology, 2012 May     [PubMed PMID: 22401913]
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study., Fournier A,Berrino F,Clavel-Chapelon F,, Breast cancer research and treatment, 2008 Jan     [PubMed PMID: 17333341]
The 2017 hormone therapy position statement of The North American Menopause Society.,, Menopause (New York, N.Y.), 2017 Jul     [PubMed PMID: 28650869]
Estrogen plus progestin and the risk of coronary heart disease., Manson JE,Hsia J,Johnson KC,Rossouw JE,Assaf AR,Lasser NL,Trevisan M,Black HR,Heckbert SR,Detrano R,Strickland OL,Wong ND,Crouse JR,Stein E,Cushman M,, The New England journal of medicine, 2003 Aug 7     [PubMed PMID: 12904517]
The risk of fatal stroke in Finnish postmenopausal hormone therapy users before and after the Women's Health Initiative: A cohort study., Tuomikoski P,Lyytinen H,Korhonen P,Hoti F,Vattulainen P,Gissler M,Ylikorkala O,Mikkola TS,, Maturitas, 2015 Jul     [PubMed PMID: 25912424]
Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study., Canonico M,Oger E,Plu-Bureau G,Conard J,Meyer G,Lévesque H,Trillot N,Barrellier MT,Wahl D,Emmerich J,Scarabin PY,, Circulation, 2007 Feb 20     [PubMed PMID: 17309934]